Other evidence has shown that reduced levels of ApoA-1 in the CSF are associated with AD, although it is not entirely clear whether this biomarker can be considered specific for AD or whether it signals the presence of neuronal damage [67]. Here, APOA1 is linked to Alzheimer disease.